Instil Bio stockholders elect directors, ratify auditor at 2026 annual meeting

Instil Bio, Inc.

84.9% of outstanding shares (5,757,919) represented at June 11, 2026 annual meeting.
George Matcham and Neil Gibson re-elected as Class II directors; Matcham 83.2% for, Gibson 81.4% for, excluding broker non-votes.
Ratification of RSM US LLP as auditor for FY2026: 5,750,869 for, 6,911 against, 139 abstentions, no broker non-votes.
Broker non-votes of 1,331,880 shares were present on director election but not auditor ratification.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Instil Bio, Inc. shareholders approved Election of Class II directors at the 2026-06-11 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Stockholders elected the following nominees to serve as Class II directors on the Company’s board of directors (the “Board”) until the Company’s 2029 Annual Meeting of Stockholders and until his successor has been duly elected and qualified.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Instil Bio, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Stockholders ratified the selection by the Audit Committee of the Board of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-26-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.